Skip to main content

Advertisement

SpringerLink
Log in

Modern treatment programs for adults with acute lymphoblastic leukemia

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

The current treatment programs for adult patients with acute lymphoblastic leukemia are modeled on pediatric regimens. The result has been complete remission rates comparable to those seen in children, but a significant proportion of adult patients relapse. Salvage therapy for patients with acute lymphoblastic leukemia continues to have limited success. Advances in molecular biology have discovered new targets for therapeutic intervention, and the introduction of some targeted agents, such as the new tyrosine kinase inhibitors and monoclonal antibodies, has led to improvements in response and survival in some subsets. The development of techniques for identification and monitoring of minimal residual leukemia has provided possible ways to predict relapse and consider early intervention. It is likely that we will further refine therapeutic approaches and improve patient outcome through the translation of biologic and molecular discoveries into effective and risk-adapted strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Faderl S, Jeha S, Kantarjian HM: The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003, 98:1337–1354.

    Article  PubMed  Google Scholar 

  2. Kebriaei P, Anastasi J, Larson RA: Acute lymphoblastic leukaemia: diagnosis and classification. Best Pract Res Clin Haematol 2002, 15:597–621.

    Article  PubMed  CAS  Google Scholar 

  3. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166–178.

    Article  PubMed  CAS  Google Scholar 

  4. Boissel N, Auclerc MF, Lheritier V, et al.: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003, 21:774–780.

    Article  PubMed  Google Scholar 

  5. Kantarjian HM, O’Brien S, Smith T, et al.: Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol 1994, 88:94–100.

    PubMed  CAS  Google Scholar 

  6. Jones B, Freeman AI, Shuster JJ, et al.: Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991, 19:269–275.

    Article  PubMed  CAS  Google Scholar 

  7. Bostrom BC, Sensel MR, Sather HN, et al.: Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 2003, 101:3809–3817.

    Article  PubMed  CAS  Google Scholar 

  8. Mitchell CD, Richards SM, Kinsey SE, et al.: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005, 129:734–745.

    Article  PubMed  CAS  Google Scholar 

  9. Hurwitz CA, Silverman LB, Schorin MA, et al.: Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000, 88:1964–1969.

    Article  PubMed  CAS  Google Scholar 

  10. Kantarjian H, Thomas D, O’Brien S, et al.: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101:2788–2801.

    Article  PubMed  CAS  Google Scholar 

  11. Larson RA, Dodge RK, Linker CA, et al.: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998, 92:1556–1564.

    PubMed  CAS  Google Scholar 

  12. Annino L, Vegna ML, Camera A, et al.: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002, 99:863–871.

    Article  PubMed  CAS  Google Scholar 

  13. Rowe JM, Buck G, Burnett AK, et al.: Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005, 106:3760–3767.

    Article  PubMed  CAS  Google Scholar 

  14. Gokbuget N, Hoelzer D, Arnold R, et al.: Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000, 14:1307–1325, ix.

    Article  PubMed  CAS  Google Scholar 

  15. Thomas X, Boiron JM, Huguet F, et al.: Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004, 22:4075–4086.

    Article  PubMed  CAS  Google Scholar 

  16. Weiss M, Maslak P, Feldman E, et al.: Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996, 14:2480–2485.

    PubMed  CAS  Google Scholar 

  17. Ravandi F: Role of cytokines in the treatment of acute leukemias: a review. Leukemia 2006, 20:563–571.

    Article  PubMed  CAS  Google Scholar 

  18. Larson RA, Dodge RK, Burns CP, et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995, 85:2025–2037.

    PubMed  CAS  Google Scholar 

  19. Ribera JM, Ortega JJ, Oriol A, et al.: Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology. Haematologica 1998, 83:222–230.

    PubMed  CAS  Google Scholar 

  20. Durrant IJ, Prentice HG, Richards SM: Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults. Br J Haematol 1997, 99:84–92.

    Article  PubMed  CAS  Google Scholar 

  21. Cassileth PA, Andersen JW, Bennett JM, et al.: Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience. Leukemia 1992, 6(Suppl 2):178–181.

    PubMed  Google Scholar 

  22. Cuttner J, Mick R, Budman DR, et al.: Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB study. Leukemia 1991, 5:425–431.

    PubMed  CAS  Google Scholar 

  23. Mandelli F, Annino L, Rotoli B: The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. GIMEMA Cooperative Group, Italy. Br J Haematol 1996, 92:665–672.

    Article  PubMed  CAS  Google Scholar 

  24. Lazarus HM, Richards SM, Chopra R, et al.: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006, 108:465–472.

    Article  PubMed  CAS  Google Scholar 

  25. Omura GA, Moffitt S, Vogler WR, Salter MM: Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 1980, 55:199–204.

    PubMed  CAS  Google Scholar 

  26. Hoelzer D, Thiel E, Loffler H, et al.: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988, 71:123–131.

    PubMed  CAS  Google Scholar 

  27. Cortes J, O’Brien SM, Pierce S, et al.: The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995, 86:2091–2097.

    PubMed  CAS  Google Scholar 

  28. Kantarjian HM, Walters RS, Smith TL, et al.: Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 1988, 72:1784–1789.

    PubMed  CAS  Google Scholar 

  29. Thiebaut A, Vernant JP, Degos L, et al.: Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000, 14:1353–1366, x.

    Article  PubMed  CAS  Google Scholar 

  30. Hunault M, Harousseau JL, Delain M, et al.: Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004, 104:3028–3037.

    Article  PubMed  CAS  Google Scholar 

  31. Wingard JR, Piantadosi S, Santos GW, et al.: Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. J Clin Oncol 1990, 8:820–830.

    PubMed  CAS  Google Scholar 

  32. Rowe JM, Buck G, Fielding A, et al.: In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from an allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2.

  33. Michallet M, Tanguy ML, Socie G, et al.: Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol 2000, 108:400–407.

    Article  PubMed  CAS  Google Scholar 

  34. Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM: Philadelphia chromosome-positive acute lymphoblastic leukemia: current concepts and future perspectives. Rev Clin Exp Hematol 2002, 6:142–160.

    Article  PubMed  CAS  Google Scholar 

  35. Wetzler M, Dodge RK, Mrozek K, et al.: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999, 93:3983–3993.

    PubMed  CAS  Google Scholar 

  36. Moorman AV, Harrison CJ, Buck GA, et al.: Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII / Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood 2007, 109:3189–3197.

    Article  PubMed  CAS  Google Scholar 

  37. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561–566.

    Article  PubMed  CAS  Google Scholar 

  38. Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530–3539.

    Article  PubMed  CAS  Google Scholar 

  39. Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965–1971.

    Article  PubMed  CAS  Google Scholar 

  40. Kano Y, Akutsu M, Tsunoda S, et al.: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001, 97:1999–2007.

    Article  PubMed  CAS  Google Scholar 

  41. Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396–4407.

    Article  PubMed  CAS  Google Scholar 

  42. Towatari M, Yanada M, Usui N, et al.: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004, 104:3507–3512.

    Article  PubMed  CAS  Google Scholar 

  43. de Labarthe A, Rousselot P, Huguet-Rigal F, et al.: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007, 109:1408–1413.

    Article  PubMed  Google Scholar 

  44. Wassmann B, Pfeifer H, Goekbuget N, et al.: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006, 108:1469–1477.

    Article  PubMed  CAS  Google Scholar 

  45. Yanada M, Takeuchi J, Sugiura I, et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460–466.

    Article  PubMed  CAS  Google Scholar 

  46. Vignetti M, Fazi P, Cimino G, et al.: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood 2007, 109:3676–3678.

    Article  PubMed  CAS  Google Scholar 

  47. Delannoy A, Delabesse E, Lheritier V, et al.: Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006, 20:1526–1532.

    Article  PubMed  CAS  Google Scholar 

  48. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531–2541.

    Article  PubMed  CAS  Google Scholar 

  49. Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542–2551.

    Article  PubMed  Google Scholar 

  50. Blum KA, Lozanski G, Byrd JC: Adult Burkitt leukemia and lymphoma. Blood 2004, 104:3009–3020.

    Article  PubMed  CAS  Google Scholar 

  51. Magrath I, Adde M, Shad A, et al.: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996, 14:925–934.

    PubMed  CAS  Google Scholar 

  52. Hoelzer D, Ludwig WD, Thiel E, et al.: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996, 87:495–508.

    PubMed  CAS  Google Scholar 

  53. Thomas DA, Cortes J, O’Brien S, et al.: Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999, 17:2461–2470.

    PubMed  CAS  Google Scholar 

  54. Rizzieri DA, Johnson JL, Niedzwiecki D, et al.: Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004, 100:1438–1448.

    Article  PubMed  CAS  Google Scholar 

  55. Cortes J, Thomas D, Rios A, et al.: Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002, 94:1492–1499.

    Article  PubMed  CAS  Google Scholar 

  56. Thomas DA, Faderl S, O’Brien S, et al.: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106:1569–1580.

    Article  PubMed  CAS  Google Scholar 

  57. Hoelzer D, Gokbuget N, Digel W, et al.: Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002, 99:4379–4385.

    Article  PubMed  CAS  Google Scholar 

  58. Thomas DA, O’Brien S, Cortes J, et al.: Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004, 104:1624–1630.

    Article  PubMed  CAS  Google Scholar 

  59. Vitale A, Guarini A, Ariola C, et al.: Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006, 107:473–479.

    Article  PubMed  CAS  Google Scholar 

  60. Dabaja BS, Ha CS, Thomas DA, et al.: The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer 2002, 94:2738–2744.

    Article  PubMed  Google Scholar 

  61. Ravandi F, Gandhi V: Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs 2006, 15:1601–1613.

    Article  PubMed  CAS  Google Scholar 

  62. O’Neil J, Calvo J, McKenna K, et al.: Activating Notch1 mutations in mouse models of T-ALL. Blood 2006, 107:781–785.

    Article  PubMed  CAS  Google Scholar 

  63. Graux C, Cools J, Melotte C, et al.: Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36:1084–1089.

    Article  PubMed  CAS  Google Scholar 

  64. Stock W, Estrov Z: Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000, 14:1289–1305, viii–ix.

    Article  PubMed  CAS  Google Scholar 

  65. Brisco J, Hughes E, Neoh SH, et al.: Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 1996, 87:5251–5256.

    PubMed  CAS  Google Scholar 

  66. Mortuza FY, Papaioannou M, Moreira IM, et al.: Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:1094–1104.

    Article  PubMed  Google Scholar 

  67. Bruggemann M, Raff T, Flohr T, et al.: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116–1123.

    Article  PubMed  Google Scholar 

  68. Raff T, Gokbuget N, Luschen S, et al.: Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007, 109:910–915.

    Article  PubMed  CAS  Google Scholar 

  69. Linker C, Damon L, Ries C, Navarro W: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:2464–2471.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, Unit 428, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Farhad Ravandi MD

Authors
  1. Farhad Ravandi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Faderl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Partow Kebriaei MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hagop Kantarjian MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Farhad Ravandi MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ravandi, F., Faderl, S., Kebriaei, P. et al. Modern treatment programs for adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep 2, 169–175 (2007). https://doi.org/10.1007/s11899-007-0023-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-007-0023-1

Keywords

Search

Navigation